Skip to main content
MiNK Therapeutics, Inc. logo

MiNK Therapeutics, Inc. — Investor Relations & Filings

Ticker · INKT ISIN · US6036931029 LEI · 529900Z7778N8ZY89B90 US Manufacturing
Open in API
Filings indexed 226 across all filing types
Latest filing 2022-11-07 Regulatory Filings
Country US United States of America
Listing US INKT

About MiNK Therapeutics, Inc.

https://www.minktherapeutics.com

MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company pioneering the development of allogeneic invariant natural killer T (iNKT) cell therapies for cancer and other immune-mediated diseases. The company's platform harnesses the dual properties of iNKT cells, which combine the potent cytotoxicity of natural killer (NK) cells with the lasting memory response of T cells to enhance both innate and adaptive immunity. Its lead product candidate, AGENT-797, is an off-the-shelf therapy administered without requiring lymphodepletion or HLA matching. It is currently in clinical trials for solid tumors, severe acute respiratory distress syndrome (ARDS), and Graft versus Host Disease (GvHD). MiNK is also developing a next-generation technology platform for engineered iNKT cells and bispecific iNKT cell engagers for precision targeting.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2022
Regulatory Filings
2022-11-07 English
S-3
Capital/Financing Update Classification · 100% confidence The document is a Form S-3 Registration Statement filed with the SEC, which is used for registering securities for public offering under the Securities Act of 1933. It includes a prospectus describing the securities to be offered, terms of the offering, and related information. This is a capital markets filing related to fundraising and securities issuance, not a financial report, earnings release, or management discussion. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial and contains detailed offering information, confirming it is not merely an announcement or a short notice.
2022-11-03 English
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text specifically mentions "Item 2.02. Results of Operations and Financial Condition" and references a press release announcing financial results for the quarter ended September 30, 2022. The document itself does not contain detailed financial statements or substantive financial data but rather furnishes a press release as an exhibit. The length is 3768 characters, which is relatively short and consistent with an announcement rather than a full report. According to the rules, such a document announcing quarterly financial results via a press release in a Form 8-K is classified as an Earnings Release (ER).
2022-11-03 English
10-Q
Interim / Quarterly Report Q3 2022
2022-11-03 English
FORM 4 SUBMISSION
Director's Dealing
2022-09-20 English
FORM 4 SUBMISSION
Director's Dealing
2022-09-20 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.